Drug intelligence / Profile preview

candesartan cilexetil + hydrochlorothiazide

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Candesartan cilexetil + hydrochlorothiazide is a fixed-dose combination medication used to treat hypertension (high blood pressure). It combines two active ingredients: candesartan cilexetil, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the action of angiotensin II at the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide increases urinary excretion of sodium and water by inhibiting sodium reabsorption in the distal tubules of the kidney, further lowering blood pressure. The combination is indicated for patients whose blood pressure is not adequately controlled with monotherapy[1][4][6][7].

Brand names
Atacand HCTAtacand PlusBlopress PlusCoKenzenECARD HDECARD LDParapres Plus 32Parapres Plus Forte
Other names
candesartan and hydrochlorothiazide
02

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on candesartan cilexetil + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan cilexetil + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call